Current treatments
Bortezomib-Cyclophosphamide-Dexamethasone (VCD) versus Bortezomib-Thalidomide-Dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. Leiba M et al. Br J Haematol. 2014 May 26. doi: 10.1111/bjh.12946. [Epub ahead of print]. Bortezomib-based induction therapy followed by intravenous busulfan-melphalan as conditioning regimen for newly diagnosed myeloma multiple patients. Blanes M…